Status:
UNKNOWN
Efficacy of Osimertinib in Patients With Lung Cancer
Lead Sponsor:
Hunan Province Tumor Hospital
Conditions:
Advanced Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recrui...
Eligibility Criteria
Inclusion
- Patients must be ≥18 years.
- Provision of fully informed consent prior to any study specific procedures.
- Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
- According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
Exclusion
- None
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 15 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06174857
Start Date
January 1 2021
End Date
September 15 2025
Last Update
December 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan Cancer hospital
Changsha, Hunan, China